Cancer Cells’ New ‘Death-Defying’ Trick Discovered | SciTechDaily
- Cancer cells are remarkably adaptable, and a new body of research is revealing just how resourceful they can be in evading treatment.
- For decades, the understanding of cancer cell death has centered around the idea of apoptosis – a programmed, orderly dismantling of the cell.
- “This flips our understanding of cancer cell death on its head,” said Matthew J.
Cancer cells are remarkably adaptable, and a new body of research is revealing just how resourceful they can be in evading treatment. Scientists have discovered a surprising survival mechanism employed by some cancer cells – a subtle activation of a process normally associated with cell death – that allows them to not only withstand targeted therapies but also to regrow and potentially cause relapse. This finding, published initially in December 2025 by researchers at the University of California San Diego, challenges long-held assumptions about how cancer cells die, and survive.
Hijacking the Death Signal
For decades, the understanding of cancer cell death has centered around the idea of apoptosis – a programmed, orderly dismantling of the cell. However, this new research suggests a more nuanced picture. Researchers found that certain cancer cells, when exposed to targeted therapy, don’t immediately undergo full-scale apoptosis. Instead, they experience a low-level activation of an enzyme normally involved in breaking down DNA during cell death. This sublethal signaling, rather than killing the cell, appears to trigger a survival response, allowing the cancer cells to regroup and regrow.
“This flips our understanding of cancer cell death on its head,” said Matthew J. Hangauer, Ph.D., assistant professor of dermatology at UC San Diego School of Medicine and a member of the Moores Cancer Center. “Cancer cells which survive initial drug treatment experience sublethal cell death signaling which, instead of killing the cell, actually helps the cancer regrow.”
Persister Cells and Treatment Resistance
The cells exhibiting this behavior have been termed “persister cells.” These aren’t genetically distinct from other cancer cells; rather, they represent a temporary state that some cells enter in response to stress, such as that imposed by chemotherapy or targeted therapy. This represents a crucial distinction, as traditional cancer drug resistance is often linked to genetic mutations that arise over time. The persister cell mechanism, being non-genetic, can emerge much more quickly, potentially explaining why some tumors return even after showing initial responsiveness to treatment.
The discovery addresses a significant challenge in cancer treatment: relapse. While initial therapies may successfully shrink tumors, a subset of cancer cells can survive and eventually drive tumor regrowth, leading to treatment failure. Understanding how these cells survive is critical to developing strategies to prevent relapse.
Implications for Future Therapies
The researchers believe that targeting the enzyme responsible for this sublethal DNA dismantling could be a promising avenue for preventing tumor recurrence. By blocking this death signaling pathway within surviving cells, it may be possible to keep tumors dormant and prevent them from regaining a foothold. This approach differs from traditional chemotherapy, which aims to kill rapidly dividing cells, and could potentially minimize the development of drug resistance.
The research builds on recent advancements in understanding cancer cell behavior. In August 2025, scientists announced a new weapon against cancer – cold plasma – capable of destroying hidden tumor cells without relying on the immune system. research, however, focuses on a different, but equally important, aspect of cancer survival: the ability of cells to adapt and endure even when faced with lethal stress.
A New Perspective on Immunotherapy
Interestingly, this discovery also has implications for immunotherapy, a treatment approach that harnesses the body’s own immune system to fight cancer. A separate study, highlighted in SciTechDaily, unveiled a method to kill cancer cells without involving the immune system. While seemingly disparate, both lines of research underscore the complexity of cancer and the need for diverse therapeutic strategies. The persister cell mechanism could potentially allow cancer cells to evade immune detection as well, highlighting the importance of addressing multiple survival pathways.
Scientists have also noted that cancer cells can “cheat death” by activating faint death signals that support their regrowth, as reported by SciTechDaily. This reinforces the idea that cancer cells are not simply passive targets but actively manipulate cellular processes to ensure their survival.
Looking Ahead
While these findings are promising, further research is needed to fully understand the persister cell mechanism and to develop effective therapies that target it. The researchers at UC San Diego are continuing to investigate the specific molecular details of this survival pathway and are exploring potential drug candidates that could block it. The ultimate goal is to develop more durable cancer treatments that prevent relapse and improve outcomes for patients.
The identification of this novel survival strategy represents a significant step forward in our understanding of cancer drug resistance. By challenging conventional wisdom about cancer cell death, this research opens up new possibilities for developing more effective and targeted therapies.